542 related articles for article (PubMed ID: 25524243)
1. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
3. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy.
Morgans AK; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Resnick MJ; Barocas DA; Penson DF
J Urol; 2015 Apr; 193(4):1226-31. PubMed ID: 25451829
[TBL] [Abstract][Full Text] [Related]
4. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
[TBL] [Abstract][Full Text] [Related]
5. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
6. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
7. Uncovering the metabolic complications of androgen deprivation therapy in patients with prostate cancer--where do we take it next?
Pinthus JH
J Urol; 2015 Jun; 193(6):1882-3. PubMed ID: 25794833
[No Abstract] [Full Text] [Related]
8. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ; Tsai HT; Haque R; Ulcickas Yood M; Van Den Eeden SK; Cassidy-Bushrow AE; Zhou Y; Keating NL; Smith MR; Aaronson DS; Potosky AL
World J Urol; 2016 Dec; 34(12):1611-1619. PubMed ID: 27084777
[TBL] [Abstract][Full Text] [Related]
9. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
[TBL] [Abstract][Full Text] [Related]
10. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
Schmid M; Hanske J; Ravi P; Krishna N; Reznor G; Meyer CP; Fisch M; Noldus J; Nguyen PL; Trinh QD
Int J Urol; 2016 Apr; 23(4):305-11. PubMed ID: 26763083
[TBL] [Abstract][Full Text] [Related]
11. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
12. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
13. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
Arch Intern Med; 2006 Feb; 166(4):465-71. PubMed ID: 16505268
[TBL] [Abstract][Full Text] [Related]
14. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
15. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer.
Gild P; Cole AP; Krasnova A; Dickerman BA; von Landenberg N; Sun M; Mucci LA; Lipsitz SR; Chun FK; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Trinh QD
J Urol; 2018 Sep; 200(3):573-581. PubMed ID: 29673944
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
17. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
18. Risk of fracture after androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
N Engl J Med; 2005 Jan; 352(2):154-64. PubMed ID: 15647578
[TBL] [Abstract][Full Text] [Related]
19. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry.
Cary KC; Singla N; Cowan JE; Carroll PR; Cooperberg MR
J Urol; 2014 Apr; 191(4):964-70. PubMed ID: 24184370
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy.
Ryu JH; Kim SJ; Kim YB; Jung TY; Ko WJ; Kim SI; Kim DY; Oh TH; Moon KT; Cho HJ; Cho JM; Yoo TK
Aging Male; 2018 Mar; 21(1):17-23. PubMed ID: 28828908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]